Abstract 678P
Background
Cancer stem cells (CSCs) are the major cause of therapy failure. CSCs are responsible for cancer relapse, metastasis, chemo-resistance, and radiation resistance. Therefore, targeting CSCs is imperative for better therapy outcomes. To date, there is no therapy precisely targeting CSCs. To fill these lacunae we have developed ExoDS a bioengineered exosome-based platform to precisely deliver chemotherapy drugs directly to CSCs effectively eliminating them.
Methods
ExoDS is an exosome-based platform that has been isolated and purified from immune cells that have been treated with a patented bioformulation and the specific drug to be incorporated within exosomes. To test the efficacy of ExoDS in targeting CSCs, we first generated and isolated CSCs from breast cancer cell lines, MCF7, MDA-MB-231, and MDA-MB-468. We next isolated CSCs from chemo-naïve breast tumor tissue samples to test the efficacy of ExoDS in targeting breast CSCs. We extensively used flow cytometric dependent analysis of AnnexinV to determine apoptosis in CSCs.
Results
Our results have shown that ExoDS can specifically identify and target CSCs with a 12-fold higher efficiency as compared to free drugs. At a cellular level, we established that ExoDS gets internalized inside CSCs within 6hrs of treatment. ExoDS was also found to target CTCs isolated from patient blood (n=5). Further analysis revealed that ExoDS spared healthy PBMCs isolated from healthy donors (n=9) as well as breast cancer patients (n=7). Our data confirmed that ExoDS can reduce chemotoxicity by more than 30%. Broadly, our results highlight the benefits of using ExoDS as compared to free chemotherapy drugs. ExoDS is a potential chemotherapy alternative.
Conclusions
Collectively, ExoDS efficiently targeted CSC in-vitro and also ex-vivo. Its specificity towards CSCs was established by the inability of ExoDS to target PBMCs derived from healthy individuals as well as patients. ExoDS can potentially target CSCs in a clinical setting making it a first-of-its-kind therapy vehicle. Targeting CSCs will revolutionize cancer treatments and will lead to better therapy outcomes. Currently, we are testing ExoDS in murine models to test it's in vivo efficacy and efficiency.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Exsure.
Funding
Biotechnology Industry Research Assistance Council (BIRAC), Government of India.
Disclosure
A. Dutta, S. Paul, S. Bhagat: Financial Interests, Institutional, Full or part-time Employment: Exsure.
Resources from the same session
126P - Biliary tract cancer (BTC) characterization on a cohort of patients (pt) from the Spanish RETUD Registry
Presenter: Adelaida Lacasta
Session: Poster session 17
127P - Prognostic significance of intratumoral and peritumoral budding in distal extrahepatic bile duct carcinoma
Presenter: Sun-Young Jun
Session: Poster session 17
128P - Biliary tract cancers: Epidemiological and prognosis trends of Latin American population
Presenter: Maria del Consuelo Diaz Romero
Session: Poster session 17
129P - Prognostic factors associated with survival in resected biliary tract cancers: A multicentre Italian experience
Presenter: Michele Ghidini
Session: Poster session 17
663P - Safety and preliminary efficacy of the KRAS G12C Inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC
Presenter: Carlos Rojas
Session: Poster session 17
664P - Final results of a phase I/II study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors
Presenter: Ryan Corcoran
Session: Poster session 17
666P - Updated efficacy and safety data of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) solid tumours
Presenter: Shun Lu
Session: Poster session 17
667P - Efficacy and safety of larotrectinib (laro) as first-line treatment for patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer
Presenter: David Hong
Session: Poster session 17